Enovis - Public Comps and Valuation Multiples

Enovis Overview

About Enovis

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Founded

1998

HQ

Employees

7.4K+

Website

enovis.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $2.1B

LTM EBITDA $386M

EV

$3.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Enovis Financials

Enovis has a last 12-month revenue of $2.1B and a last 12-month EBITDA of $386M.

In the most recent fiscal year, Enovis achieved revenue of $2.1B and an EBITDA of -$481M.

Enovis expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Enovis valuation multiples based on analyst estimates

Enovis P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$1.7B	$2.1B	XXX	XXX	XXX
Gross Profit	$869M	$991M	XXX	XXX	XXX
Gross Margin	51%	47%	XXX	XXX	XXX
EBITDA	$170M	-$481M	XXX	XXX	XXX
EBITDA Margin	10%	-23%	XXX	XXX	XXX
Net Profit	-$13.3M	-$33.3M	XXX	XXX	XXX
Net Margin	-1%	-2%	XXX	XXX	XXX
Net Debt	$235M	$430M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Enovis Stock Performance

As of April 15, 2025, Enovis's stock price is $32.

Enovis has current market cap of $1.8B, and EV of $3.2B.

See Enovis trading valuation data

Enovis Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.2B	$1.8B	XXX	XXX	XXX	XXX	$2.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Enovis Valuation Multiples

As of April 15, 2025, Enovis has market cap of $1.8B and EV of $3.2B.

Enovis's trades at 1.5x LTM EV/Revenue multiple, and 8.3x LTM EBITDA.

Analysts estimate Enovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Enovis and 10K+ public comps

Enovis Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$3.2B	XXX	XXX	XXX
EV/Revenue	1.5x	XXX	XXX	XXX
EV/EBITDA	-6.7x	XXX	XXX	XXX
P/E	-2.2x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-47.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Enovis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Enovis Valuation Multiples

Enovis's NTM/LTM revenue growth is 5%

Enovis's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Enovis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Enovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Enovis and other 10K+ public comps

Enovis Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	23%	XXX	XXX	XXX	XXX
EBITDA Margin	-23%	XXX	XXX	XXX	XXX
EBITDA Growth	-383%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	-17%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.3M	XXX	XXX	XXX	XXX
Opex per Employee	$0.2M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	4%	XXX	XXX	XXX	XXX
Opex to Revenue	61%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry